Granulocyte colony-stimulating factor (G-CSF) has been widely used in the field of allogeneic haematopoietic stem cell transplantation (allo-HSCT) for priming donor stem cells from the bone marrow (BM) to peripheral blood (PB) to collect stem cells more conve- 
allo-HSCT procedures consist mostly of bone marrow (BM) cells or granulocyte colony-stimulating factor (G-CSF)-primed peripheral blood stem cells (GPB) or G-CSF-primed bone marrow (GBM). Natural killer (NK) cells mediate the early, non -adaptive responses against viruses
and intracellular bacteria and modulate the activity of effector cells within the adaptive and innate immune systems. 1 NK cells mediate these effects through the production of cytokines and the direct killing of transformed or infected cells. [2] [3] [4] The function of NK cells is modulated by the balance of expression of inhibitory killer immunoglobulinlike receptors (KIRs) and activating receptors on NK cells. Previous studies have shown that donor and recipient KIR ligand mismatch can initiate donor NK cell alloreactivity, leading to decreased leukaemia relapse and decreased GVHD incidence post-haploidentical transplantation with T cell depletion in vitro. 5 However, the predictive value of KIR ligand mismatch on clinical outcome has been inconsistent among different transplantation centres utilizing different protocols. 6, 7 One of the most important reasons would be the in vivo application of G-CSF for donor stem cell preparation that decreased the cytotoxicity of NK cells. 8, 9 However, previous studies have considered only the cytotoxic roles of NK cells under haploidentical transplantation while neglecting the immune regulatory effect of NK cells.
Although both GBM and GPB contain large numbers of mature donor T cells that could cause GVHD, 10 clinical data have demonstrated that the cumulative incidence of acute GVHD is acceptable with these cell sources. 11 Based on the cytokine secretion model,
CD4
+ T cells can be classified as type 1 (Th1), type 2 (Th2) and type 17
(Th17) subpopulations of T cells. [12] [13] [14] [15] [16] [17] Similar to Th1 and Th2 cells, human NK cells cultured in the presence of IL-12 or IL-4 can differentiate into populations with distinct patterns of cytokine secretion. [18] [19] [20] [21] [22] [23] Specifically, IFN-c-secreting NK cells (NK1) were shown to be important for infection control, 24, 25 while IL13-secreting NK cells (NK2), which contribute to IgE production by B cells, participate in the regulation of allergic airway responses. [21] [22] [23] In addition, peripheral blood NK cells producing TGF-b (NK3) and IL-10 (NKr) have been shown to have a regulatory function in humans. [26] [27] [28] [29] Our previous work demonstrated that the in vivo application of G-CSF induced T cell hyporesponsiveness. In particular, the levels of Th1 and Th17 cells were decreased, while those of Th2 cells were increased in BM and PB grafts using G-CSF. [13] [14] [15] 30 However, the content and function of NK cells in BM before and after G-CSF in vivo application have not been analysed. line at an effector-to-target ratio of 5:1 for 5 hours. GolgiStop (0.7 lL/mL) (BD Biosciences) were added after 1 hour. CD107a and IFN-gamma production by NK cells was measured using the Pharmingen Intracellular Staining Kit (BD Pharmingen, San Diego, CA, USA).
| Transplant procedure and definition
All patients received a myeloablative regimen, and conditioning was performed as previously described. 31, 32, 34, 35 In HLA-matched sibling transplants, 32 
| Statistical analysis
To test differences in NK cell expression of receptors or cytokine secretion between NGPB and GPB; GPB and GBM; and NGBM and GBM, a Wilcoxon signed-rank test or paired-sample t test was used. Associations between the dose and percentage of NK1, NK2, NK3 and NKr cells infused in GBM or GPB and GVHD were calculated using cumulative incidence curves to accommodate competing risks. Gray's test was used in the cumulative incidence analyses.
3 | RESULTS
| Effect of G-CSF on NK cell expansion
The percentages of overall NK cells among nuclear cells and lymphoid cells were significantly decreased in BM and PB cells post-G-CSF in vivo application (P < .05, Figure 1A ,B). The ratio of T cells and NK cells was significantly decreased in PB and BM after G-CSF treatment (P < .05, Figure 1C ). The relative expansion of the CD56 bri NK subsets led to a decreased ratio of CD56 dim and CD56 bri NK cells in GBM and GPB compared to that in NGBM and NGPB, respectively (P < .05, Figure 1D ).
Considering that the expression levels of inhibitory receptors, activating receptors, adhesion molecules and chemokine receptors play important roles in regulating NK cell function, the expression levels of CD158a, CD158b, CD158e, CD94, NKG2A, CD62L, CD54, CD11a, CX3CR1, CXCR4, CCR7 and G-CSFR on NK cells were evaluated before and after G-CSF in vivo application. The expression levels of all tested molecules on NK cells in GBM were comparable Figure 1H ). In contrast,the expression of CX3CR1 on NK cells in GPB was significantly decreased compared to those in NGPB ( Figure 1I ). The MFI of CD62L, CD54, CD94 and CXCR4 on NK cells in GPB were also higher compared to those in NGPB (data not shown). The percentage of CD11a on NK cells was comparable among NGPB, GPB, NGBM and GBM, but the MFI of CD11a on NK cells in GPB had a trend to be higher compared to those in NGPB and GBM ( Figure 1J ). Based on the cut-off value for the NK1 cell dose and chronic GVHD (4.8 9 10 6 /kg, sensitivity 72.2%, specificity 61.9%, P = .040), patients were subgrouped into either the high NK1 group (n = 21) or low NK1 group (n = 18). Patients in the high NK1 group demonstrated a higher cumulative incidence of overall cGVHD (61.91 AE 11.11% vs 27.78 AE 10.93%; P = .026; Figure 5B ) and extensive cGVHD (45.41 AE 12.86% vs 11.46 AE 7.9%; P = .04; Figure 5C ) than patients in the low NK1 group. The patient characteristics of the high and low NK1 groups (as shown in Table 1 ) were comparable, with the exception of the NK1 cell dose in the allografts.
G H F I G U R E 1 Comparison of NK cells between NGPB and GPB, NGBM and GBM, and GBM and GPB. A and B show comparisons of the percentage of NK cells among nuclear cells (A) and lymphoid cells (B) (n = 15); C and D show the comparison of the ratio of T and NK cells (C) as well as the ratio of CD56 dim and CD56 bright NK cells (D) (n = 15); E, F, G, H, I and J show comparisons of the expression of CD62L (E), CD54 (F), CD94 (G), CXCR4 (H), CX3CR1 (I) and
No associations were found between the NK subpopulation numbers in allografts and the relapse, treatment-related mortality (TRM), overall survival (OS) and event-free survival (EFS) rates (data not shown).
| DISCUSSION
In this study, the following main findings were made: 1) in vivo application of G-CSF not only decreased the percentage of NK cells but also modulated NK subpopulations, leading to an increased ratio of A previous study demonstrated that myeloid progenitors were expanded, and lymphoid progenitors were decreased after the in vivo application of G-CSF. 8 Consistent with this previous report, 8 the percentages of NK cells among GBM and GPB were significantly decreased in our study; therefore, the ratio of T and NK cells in GBM or GPB was significantly increased compared to that in NGBM and NGPB, respectively. However, we found that the ratio of CD56 bri to CD56 dim subsets was significantly increased in GBM and GPB compared to that in NGBM and NGPB, respectively, which differed from this previous report. 8 Miller JS et al demonstrated that G-CSF in vivo treatment had no effect on the proportion of CD56 bri NK cells. 8 The tributed to acute GVHD. 42 Therefore, the contribution of NK1 cells to the prognosis of chronic GVHD warrants further study.
Meanwhile, in accordance with a previous report, 8, 9 we found that the cytotoxicity of overall NK cells, CD56 bri NK subsets as well as CD56 dim NK subsets in GPB was significantly decreased compared to that in NGPB, which could not be rescued by IL-2 stimulation. Based on the data in this study, we propose the following 
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